|Mr. Kevin S. Boyle Sr.||CEO & Director||347.81k||N/A||1974|
|Mr. Michael Wong||VP of Fin. & Principal Accounting Officer||N/A||N/A||1980|
|Ms. Melinda Lackey||Sr. VP of Legal & Sec.||N/A||N/A||1977|
|Dr. David M. Mauney M.D.||Consultant||N/A||N/A||1969|
|Dr. Drew C. Deniger Ph.D.||VP of R&D||N/A||N/A||1980|
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Alaunos Therapeutics, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 3; Compensation: 8.